Gelfand, Joel M.Armstrong, April W.Bell, StacieAnesi, George L.Blauvelt, AndrewCalabrese, CassandraDommasch, Erica D.Feldman, Steve R.Gladman, DafnaKircik, LeonLebwohl, MarkLo Re, Vincent, IIIMartin, GeorgeMerola, Joseph F.Scher, Jose U.Schwartzman, SergioTreat, James R.Van Voorhees, Abby S.Ellebrecht, Christoph T.Fenner, JustineOcon, AnthonySyed, Maha N.Weinstein, Erica J.Smith, JessicaGondo, GeorgeHeydon, SueKoons, SamanthaRitchlin, Christopher T.2020-10-302020-10-302020Gelfand, J. M., Armstrong, A. W., Bell, S., Anesi, G. L., Blauvelt, A., Calabrese, C., Dommasch, E. D., Feldman, S. R., Gladman, D., Kircik, L., Lebwohl, M., Lo, R. V., Martin, G., Merola, J. F., Scher, J. U., Schwartzman, S., Treat, J. R., Van Voorhees, A. S., Ellebrecht, C. T., … Ritchlin, C. T. (2020). National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2020.09.001https://hdl.handle.net/1805/24211Objective To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic. Study design A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted. Results The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus. Limitations The evidence behind many guidance statements is limited in quality. Conclusion These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.enPublisher PolicybiologicsCOVID-19psoriasisArticle